Physician profile
Katrina Barnes
NPI 1003034281
$784.42
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $506 · 2021: $24.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $168.09 | 2019-2020 | |
| Amarin Pharma, INC. | $154.61 | 2019-2020 | |
| Amgen INC. | $66.52 | 2020 | |
| Boston Scientific Corporation | $65.12 | 2020 | |
| Pfizer INC. | $47.64 | 2019-2020 | |
| Allergan, INC. | $40.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.08 | 2020-2021 | |
| Glaxosmithkline, LLC. | $34.33 | 2019 | |
| Abbvie INC. | $31.14 | 2019 | |
| Lilly USA, LLC | $28.35 | 2019 | |
| Vivus LLC | $23.82 | 2020 | |
| Horizon Therapeutics Plc | $23.34 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.22 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.07 | 2020 | |
| Ethicon US, LLC | $12.87 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.